J. P. Olié, Les effets indésirables des neuroleptiques, 1990.

D. Ginestet, Guide du bon usage des psychotropes, 1997.

N. Franck and T. F. , Pharmacologie et mode d'action des neuroleptiques Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects, EMC psychiatrie Pharmacol Rev, issue.1, pp.53-119, 2001.

P. Seeman, Atypical antipsychotics: mechanism of action, Can J Psychiatry, vol.47, issue.1, pp.27-38, 2002.

J. Geddes, Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Review of atypical antipsychotics and weight gain, BMJ Lancet J Clin Psychiatry, vol.10, issue.11, pp.321-1371, 2000.

K. G. Alberti, P. Zimmet, and J. Shaw, The metabolic syndrome???a new worldwide definition, The Lancet, vol.366, issue.9491, pp.366-1059, 2005.
DOI : 10.1016/S0140-6736(05)67402-8

M. Plaze, Comprendre les effets latéraux des antipsychotiques atypiques. L'Encéphale, pp.237-241, 2008.
DOI : 10.1016/s0013-7006(08)75521-0

D. C. Henderson, Weight gain with atypical antipsychotics: evidence and insights, J Clin Psychiatry, vol.68, issue.12, pp.18-26, 2007.

D. B. Allison, Antipsychotic-induced weight gain: a comprehensive research synthesis

M. J. Sernyak, Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia, American Journal of Psychiatry, vol.159, issue.4, pp.561-567, 2002.
DOI : 10.1176/appi.ajp.159.4.561

G. S. Kabinoff, Metabolic Issues With Atypical Antipsychotics in Primary Care, The Primary Care Companion to The Journal of Clinical Psychiatry, vol.05, issue.01, pp.6-14, 2003.
DOI : 10.4088/PCC.v05n0103

J. M. Meyer, diabetes: review of prospective clinical data Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1, Br J Psychiatry Schizophr Res, vol.47, issue.1011-3, pp.87-93, 2004.

D. Hert, M. , R. Van-winckel, and D. Van-eyck, Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication, Schizophrenia Research, vol.83, issue.1, pp.87-93, 2006.
DOI : 10.1016/j.schres.2005.12.855

D. Hert, M. , V. Schreurs, K. Sweers-parks, and J. , Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in firts-episode patients with schizophrenia: A retroscpetive chart review Severe mental illness and risk of cardiovascular disease Morbidity and mortality in people with serious mental illness Medical directors council, National association of state mental health program directors, pp.295-303, 1924.

S. Saha, D. Chant, J. Mcgrath-nasrallah, and H. A. , A Systematic Review of Mortality in Schizophrenia, Archives of General Psychiatry, vol.64, issue.10, pp.1123-311, 2006.
DOI : 10.1001/archpsyc.64.10.1123

D. Hert and M. , Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC), European Psychiatry, vol.24, issue.6, pp.412-424, 2009.
DOI : 10.1016/j.eurpsy.2009.01.005

D. Hert, M. , R. Van-winkel, and D. Van-eyck, Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study AFSSAPS. Recommandations pour le suivi cardio-métabolique des patients traités par antipsychotiques, Clin Pract Epidemiol Ment Health, vol.29, pp.2-14, 2006.

C. Richard, M. Lussier, and L. Communication-professionnelle-en-santé, Montréal : Éditions du renouveau pédagogique. ERPI, 2005. 31. Code-de-déontologie-médicale Article 58, Consultation en l'absence du médecin habituel Available from: http://www.conseilnational .medecin.fr/article/article-58-consultation-en-l-absence-du-medecin-habituel-282. 32. Code-de-déontologie-médicale. Article 60, Appel à un consultant ou un spécialiste Exercice en équipe, Décembre Article, vol.64, 2009.

D. O. Perkins and E. H. Morrato, Adherence to antipsychotic medications Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs Arch Gen Psychiatry Monitoring of patients given second-generation antipsychotic agents Practice guideline for the treatment of patients with schizophrenia, second edition, J Clin Psychiatry Psychiatr Serv Am J Psychiatry, vol.60, issue.402, pp.17-24, 1999.

. American-diabetes-association, Consensus development conference antipsychotic drug and obesity and diabetes. Diabetes care The effects of antipsychotics on serum lipids: a comprehensive review, Schizophr Res, vol.27, issue.70, pp.596-601, 2004.

D. Nayer and A. , Belgian consensus on métabolique problems associated with atypical antipsychotics, Int J Psychiatr Clin prat, issue.9, pp.130-137, 2005.

D. Van-eyck, Oral glucose tolerance test in schizophrenia for « dummies », making sense of potentially predictive prediabetic insulin and glucose curves, Schizophr Bull ANAES, pp.31572-31617, 2003.